NFKB1 and in situ carcinoma: The use of CIS increased serum NF-κB (+11%,p < 0.05), TNF-α (+1.4%), IL-6 (+21%,p < 0.001), MDA (+20%), TOS (+21%), and IMA (+11%), while reducing TAS by 25% (p < 0.05), as shown inTable 1.